These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 31012492)
1. Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication. Athreya AP; Neavin D; Carrillo-Roa T; Skime M; Biernacka J; Frye MA; Rush AJ; Wang L; Binder EB; Iyer RK; Weinshilboum RM; Bobo WV Clin Pharmacol Ther; 2019 Oct; 106(4):855-865. PubMed ID: 31012492 [TBL] [Abstract][Full Text] [Related]
2. Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication. Joyce JB; Grant CW; Liu D; MahmoudianDehkordi S; Kaddurah-Daouk R; Skime M; Biernacka J; Frye MA; Mayes T; Carmody T; Croarkin PE; Wang L; Weinshilboum R; Bobo WV; Trivedi MH; Athreya AP Transl Psychiatry; 2021 Oct; 11(1):513. PubMed ID: 34620827 [TBL] [Abstract][Full Text] [Related]
3. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. Gupta M; Neavin D; Liu D; Biernacka J; Hall-Flavin D; Bobo WV; Frye MA; Skime M; Jenkins GD; Batzler A; Kalari K; Matson W; Bhasin SS; Zhu H; Mushiroda T; Nakamura Y; Kubo M; Wang L; Kaddurah-Daouk R; Weinshilboum RM Mol Psychiatry; 2016 Dec; 21(12):1717-1725. PubMed ID: 26903268 [TBL] [Abstract][Full Text] [Related]
4. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Biernacka JM; Sangkuhl K; Jenkins G; Whaley RM; Barman P; Batzler A; Altman RB; Arolt V; Brockmöller J; Chen CH; Domschke K; Hall-Flavin DK; Hong CJ; Illi A; Ji Y; Kampman O; Kinoshita T; Leinonen E; Liou YJ; Mushiroda T; Nonen S; Skime MK; Wang L; Baune BT; Kato M; Liu YL; Praphanphoj V; Stingl JC; Tsai SJ; Kubo M; Klein TE; Weinshilboum R Transl Psychiatry; 2015 Apr; 5(4):e553. PubMed ID: 25897834 [TBL] [Abstract][Full Text] [Related]
5. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Ji Y; Hebbring S; Zhu H; Jenkins GD; Biernacka J; Snyder K; Drews M; Fiehn O; Zeng Z; Schaid D; Mrazek DA; Kaddurah-Daouk R; Weinshilboum RM Clin Pharmacol Ther; 2011 Jan; 89(1):97-104. PubMed ID: 21107318 [TBL] [Abstract][Full Text] [Related]
6. Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. Qin S; Eugene AR; Liu D; Zhang L; Neavin D; Biernacka JM; Yu J; Weinshilboum RM; Wang L Clin Pharmacol Ther; 2020 Mar; 107(3):662-670. PubMed ID: 31628858 [TBL] [Abstract][Full Text] [Related]
7. Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction. Nguyen TTL; Liu D; Ho MF; Athreya AP; Weinshilboum R Front Pharmacol; 2020; 11():614048. PubMed ID: 33510640 [TBL] [Abstract][Full Text] [Related]
8. Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder. Shelton RC; Parikh SV; Law RA; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Macaluso M; Hain DT; Aguilar AL; Brown K; Lewis DJ; Jablonski MR; Greden JF Psychiatry Res; 2020 Aug; 290():113017. PubMed ID: 32485484 [TBL] [Abstract][Full Text] [Related]
9. Inclusion of genetic variants in an ensemble of gradient boosting decision trees does not improve the prediction of citalopram treatment response. Shumake J; Mallard TT; McGeary JE; Beevers CG Sci Rep; 2021 Feb; 11(1):3780. PubMed ID: 33580158 [TBL] [Abstract][Full Text] [Related]
10. Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. Ji Y; Biernacka J; Snyder K; Drews M; Pelleymounter LL; Colby C; Wang L; Mrazek DA; Weinshilboum RM Pharmacogenomics J; 2012 Feb; 12(1):78-85. PubMed ID: 20877297 [TBL] [Abstract][Full Text] [Related]
11. New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation. Fabbri C; Tansey KE; Perlis RH; Hauser J; Henigsberg N; Maier W; Mors O; Placentino A; Rietschel M; Souery D; Breen G; Curtis C; Sang-Hyuk L; Newhouse S; Patel H; Guipponi M; Perroud N; Bondolfi G; O'Donovan M; Lewis G; Biernacka JM; Weinshilboum RM; Farmer A; Aitchison KJ; Craig I; McGuffin P; Uher R; Lewis CM Pharmacogenomics J; 2018 May; 18(3):413-421. PubMed ID: 29160301 [TBL] [Abstract][Full Text] [Related]
13. Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data. Taliaz D; Spinrad A; Barzilay R; Barnett-Itzhaki Z; Averbuch D; Teltsh O; Schurr R; Darki-Morag S; Lerer B Transl Psychiatry; 2021 Jul; 11(1):381. PubMed ID: 34238923 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947 [TBL] [Abstract][Full Text] [Related]
15. ERICH3: vesicular association and antidepressant treatment response. Liu D; Zhuang Y; Zhang L; Gao H; Neavin D; Carrillo-Roa T; Wang Y; Yu J; Qin S; Kim DC; Liu E; Nguyen TTL; Biernacka JM; Kaddurah-Daouk R; Dunlop BW; Craighead WE; Mayberg HS; Binder EB; Frye MA; Wang L; Weinshilboum RM Mol Psychiatry; 2021 Jun; 26(6):2415-2428. PubMed ID: 33230203 [TBL] [Abstract][Full Text] [Related]
16. FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Ellsworth KA; Moon I; Eckloff BW; Fridley BL; Jenkins GD; Batzler A; Biernacka JM; Abo R; Brisbin A; Ji Y; Hebbring S; Wieben ED; Mrazek DA; Weinshilboum RM; Wang L Pharmacogenet Genomics; 2013 Mar; 23(3):156-66. PubMed ID: 23324805 [TBL] [Abstract][Full Text] [Related]
17. Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data. Bobo WV; Angleró GC; Jenkins G; Hall-Flavin DK; Weinshilboum R; Biernacka JM Hum Psychopharmacol; 2016 May; 31(3):185-92. PubMed ID: 26999588 [TBL] [Abstract][Full Text] [Related]
18. Influence and interaction of genetic, cognitive, neuroendocrine and personalistic markers to antidepressant response in Chinese patients with major depression. Bi Y; Ren D; Guo Z; Ma G; Xu F; Chen Z; An L; Zhang N; Ji L; Yuan F; Liu L; Hou B; Yang F; Yu S; Yi Z; Xu Y; He L; Sun X; Dong Z; Wu S; Zhao L; Cai C; Li X; Yu T; Shi Y; He G Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110036. PubMed ID: 32702381 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial. Rajpurkar P; Yang J; Dass N; Vale V; Keller AS; Irvin J; Taylor Z; Basu S; Ng A; Williams LM JAMA Netw Open; 2020 Jun; 3(6):e206653. PubMed ID: 32568399 [TBL] [Abstract][Full Text] [Related]
20. Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. MahmoudianDehkordi S; Ahmed AT; Bhattacharyya S; Han X; Baillie RA; Arnold M; Skime MK; John-Williams LS; Moseley MA; Thompson JW; Louie G; Riva-Posse P; Craighead WE; McDonald W; Krishnan R; Rush AJ; Frye MA; Dunlop BW; Weinshilboum RM; Kaddurah-Daouk R; Transl Psychiatry; 2021 Mar; 11(1):153. PubMed ID: 33654056 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]